03 November 2013
Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.
ReVision Optics – 2013 Fierce 15
21 October 2013
ReVision Optics is upping the technological game with vision improvement devices and technology. The company's Raindrop Near Vision microscopic hydrogel inlay is designed to treat patients with presbyopia, the loss of near vision in patients when they reach middle age and typically need reading glasses. CEO John Kilcoyne said doctors can now also use RainDrop in patients receiving a separate procedure to correct their distance vision.
FierceMedicalDevices' 2013 Fierce 15
21 October 2013
This year's crop endured the struggles many startups face and came out ahead. They've attracted substantial funding from major investors in a tough market, proving the worth of their products. Many are also already in--or close to--market with their signature products, a sign of stability that draws investor commitments much more these days than companies on the earlier side of development.
Hydrogel inlay improves uncorrected near visual acuity in presbyopic emmetropic eyes
26 September 2013
The inlay creates multifocality at the corneal plane, with near vision on the visual axis and a transition to intermediate, distance vision out to the periphery.
05 September 2013
Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions.
Corneal inlays have the potential to 'treat millions'
30 June 2013
Corneal inlays are designed to treat presbyopia by being inserted in the non-dominant eye and correcting for near vision; distance vision remains (mostly) unaffected.
Nanotechnology Didn't Shrink and Disappear; In Fact, It's Everywhere
04 February 2013
Nanotechology, which involves controlling matter at the molecular and atomic levels, was a much-hyped investment theme a decade ago. It’s since become widely used in commercial products ranging from solar panels to semiconductors, but investing in nanotech requires patience.
01 February 2013
Tracey Sunderland, COO, Coda Therapeutics Inc: “We think we’ve got something that has the potential to be a real game changer in this space particularly due to the fact that there are no therapeutic compounds on the market currently.”
09 January 2013
CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.
Marinus Pharmaceuticals Adds $21M Series C
07 January 2013
Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024